The American biotech company Moderna announced that its COVID-19 vaccine is highly effective in children between the ages of 12 and 17, based on comprehensive results from clinical trials.
Moderna said it plans to submit an application for authorization to use its vaccine for this age group in early June to regulators around the world.
Another vaccine, the one from Pfizer / BioNTech, has already been licensed for adolescents in several countries, including the United States.
The vaccine was shown to be highly effective in preventing COVID-19 in adolescents, Moderna boss Stéphane Bancel was quoted as saying in a statement.
“We are going to present the results to the FDA (US Food and Drug Administration) and other regulators around the world in early June and apply for an authorization,” he continued.
Moderna’s study was done with more than 3,700 participants between the ages of 12 and 17 in the United States, of whom two-thirds received the vaccine and one-third a placebo.
“After two doses, no cases of COVID-19 were observed in the vaccinated group, against four cases in the placebo group, resulting in a vaccine effectiveness of 100% 14 days after the second dose,” stated Moderna in your release.
After one dose, an efficacy of 93% was observed, according to the company.
The vaccine was generally well tolerated and no safety concerns have been identified so far, he said.